Impact of Inflammatory Cytokine Gene Polymorphisms on Developing Acute Graft-versus-Host Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Table 1

Association between clinical variable and aGvHD.

	Tot. = 117	%	GVHD I–IV			GVHD II–IV			GVHD III-IV
			Tot. = 73	%		Tot. = 48	%	P	Tot. = 13	%
Sex
Recipient
M	82	70.0%	48	58.5%	0.21	32	39.0%	0.54	7	8.5%	0.20
F	35	30.0%	25	71.4%		16	45.7%		6	17.1%
Donor
M	73	62.3%	47	64.3%	1.00	31	42.4%	0.70	9	12.3%	0.76
F	44	37.7%	26	59.0%		17	38.6%		4	9.0%
Underlying disease
Leukemia and lymphoma	81	69.2%	50	61.7%	0.33	36	44.4%	0.47	8	9.8%	0.28
Solid tumors	17	14.5%	13	76.4%		5	29.4%		1	5.8%
Nononcologic disease	19	16.3%	10	52.6%		7	36.8%		4	21.0%
Transplantation type
Matched, related	43	36.8%	25	58.1%	0.74	17	39.5%	0.91	4	9.3%	0.37
Matched, unrelated	47	63.8%	30	63.8%		20	42.5%		4	8.5%
Mismatch, unrelated	27	23.0%	18	66.6%		12	44.4%		5	18.5%
Conditioning regimen
TBI-based	22	18.9%	16	72.7%	0.33	13	59.0%	0.10	3	13.6%	0.70
BU-based	95	81.1%	57	60.0%		35	36.8%		10	10.5%
Stem cells sources
Bone marrow	92	78.6%	60	65.2%	0.025	41	44.5%	0.17	7	7.6%	0.003^*
PBSC	25	21.4%	13	52.0%		7	28.0%		6	24.0%
GVHD prophylaxis
CSA only	33	28.2%	19	57.5%	0.52	11	33.3%	0.30	2	6.0%	0.34
CSA + other	84	71.8%	54	64.2%		37	44.0%		11	13.0%
Number of HSCT
1	101	86.3%	62	61.3%	0.78	40	39.6%	0.58	11	10.8%	1.00
>1	16	23.7%	11	68.5%		8	50.0%		2	12.5%

M: male; F: female; yrs: years; TBI: total body irradiation; BU: busulfan; GVHD: graft versus host disease; CSA: cyclosporine A; PBSC: peripheral blood stem cells; ^* < 0.05.